Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial

JAMA Oncology
Heikki JoensuuHenrik Lindman

Abstract

Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. While the standard duration of trastuzumab treatment is 12 months, the benefits and harms of trastuzumab continued beyond the chemotherapy are unclear. To evaluate the efficacy and safety of adjuvant trastuzumab continued beyond chemotherapy in women treated with up-front chemotherapy containing a taxane and trastuzumab. Open-label, randomized (1:1) clinical trial including women with HER2-positive breast cancer. Chemotherapy was identical in the 2 groups, consisting of 3 cycles of 3-weekly docetaxel (either 80 or 100 mg/m2) plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide. Thereafter, no trastuzumab was administered in the 9-week group, whereas controls received trastuzumab to complete 1 year of administration. Disease-free survival (DFS) was compared between the groups using a Cox model and the noninferiority approach. The estimated sample size was 2168 patients (1-sided testing, with a relative noninferiority margin of 1.3). From January 3, 2008, to December 16, 2014, 2176 patients were accrued from 7 countries. Doc...Continue Reading

Associated Clinical Trials

References

May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L Spector, Kimberly L Blackwell
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRobert B Jenkins
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Ana Catarina PintoMartine Piccart-Gebhart
Oct 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mariana Chavez-MacGregorSharon H Giordano
Jun 11, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evandro de AzambujaThomas M Suter
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
May 4, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisUNKNOWN Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Sep 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pooja P AdvaniEdith A Perez
Oct 18, 2015·Journal of the National Cancer Institute·Hart A GoldharKelvin K W Chan
Jun 6, 2017·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN APHINITY Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Nov 24, 2018·Expert Review of Clinical Pharmacology·Angela EspositoGiuseppe Curigliano
Jan 19, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciV Guarneri
Apr 18, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E de Azambuja, M Piccart-Gebhart
May 18, 2019·American Society of Clinical Oncology Educational Book·Ian TannockLeonard B Saltz
Aug 8, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Zachary VeitchSasha Lupichuk
Sep 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ConteV Guarneri
Sep 25, 2019·Nature Reviews. Disease Primers·Nadia HarbeckFatima Cardoso
Jul 19, 2019·The Oncologist·Carly C BarronDarryl P Leong
Feb 19, 2020·CA: a Cancer Journal for Clinicians·Javier CortesJoaquín Arribas
Apr 3, 2020·American Society of Clinical Oncology Educational Book·Danielle FileLisa A Carey
Aug 20, 2020·CA: a Cancer Journal for Clinicians·Grace M ChoongCiara C O'Sullivan
Apr 29, 2020·Journal of the National Cancer Institute·Anne H Blaes, Chau Dang
Mar 15, 2019·Cost Effectiveness and Resource Allocation : C/E·Noga GershonDaniel A Goldstein
May 15, 2019·Current Opinion in Cardiology·Robert S Copeland-HalperinAnthony F Yu
May 15, 2019·Expert Review of Anticancer Therapy·N KoteckiA Awada
Oct 23, 2019·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Dec 15, 2019·Nature Reviews. Clinical Oncology·Kristina GoutsouliakRachel Schiff
May 21, 2019·International Journal of Cancer. Journal International Du Cancer·Dario TrapaniAju Mathew
Jul 26, 2019·Nature Reviews. Clinical Oncology·Noam Pondé, Evandro de Azambuja
Oct 17, 2018·Current Opinion in Oncology·Maria Vittoria DieciValentina Guarneri
Sep 13, 2020·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Sep 16, 2020·Seminars in Oncology·Lauren Chiec, Ami N Shah
Apr 5, 2021·Lancet·Sibylle LoiblGiuseppe Curigliano
Nov 25, 2020·Clinical Breast Cancer·Laura TakalaMaarit Bärlund

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.